DEF: Immunic Seeks Shareholder Approval for Reverse Stock Split

Immunic, Inc. is calling a special meeting on April 14, 2026, to seek stockholder approval for a reverse stock split to maintain its Nasdaq listing and facilitate future capital raising.

Summary

• A Special Meeting of stockholders is scheduled for April 14, 2026, at 9:00 a.m. Eastern Standard time, to be held virtually via the Internet.
• Stockholders will vote on a proposal to authorize the Board of Directors to amend the company's certificate of incorporation to effect a reverse stock split of common stock at a ratio in the range of 1-for-10 to 1-for-30, with the Board anticipating a range not exceeding 1-for-10 to 1-for-20.
• The primary objective of the reverse stock split is to increase the per-share trading price of common stock to regain compliance with the Nasdaq Minimum Bid Price Requirement of $1.00 per share.
• Immunic received a notice from Nasdaq on June 27, 2025, indicating non-compliance with the $1.00 minimum bid price rule.
• The company's common stock was transferred from the Nasdaq Global Select Market to the Nasdaq Capital Market on January 7, 2026, granting an additional 180-day grace period until June 22, 2026, to regain compliance.
• Failure to approve the reverse stock split could lead to delisting from Nasdaq, potentially resulting in trading on an over-the-counter market, reduced liquidity, and inhibited capital raising activities.
• On February 12, 2026, Immunic entered into a Securities Purchase Agreement with institutional and accredited investors for an offering of pre-funded warrants and common stock warrants, which closed on February 17, 2026.
• The Securities Purchase Agreement obligates Immunic to file this proxy statement and obtain stockholder approval for the Reverse Stock Split Amendment; failure to do so would constitute a breach of the agreement.
• As of February 20, 2026, there were 130,464,825 shares of common stock issued and outstanding.
• A reverse stock split would affect all holders of common stock uniformly, proportionally reducing the number of outstanding shares and adjusting the exercise price and number of shares for outstanding options and warrants.
• Fractional shares will not be issued; stockholders who would otherwise hold a fractional share interest will receive a cash payment based on the market price.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a necessary defensive action to maintain market access and fulfill financing terms, rather than a sign of strong operational performance. The underlying issue of a low stock price and delisting risk is a significant negative, despite the proactive measure.

Positives

• A reverse stock split could enable Immunic to regain compliance with Nasdaq's Minimum Bid Price Requirement, preventing delisting.
• Maintaining a Nasdaq listing can allow a broader range of institutional investors to invest, potentially increasing trading volume and liquidity of the common stock.
• An increased stock price could attract more analyst and broker interest, as many firms have policies discouraging investment in low-priced stocks.
• Approval of the reverse stock split is a condition of a recent Securities Purchase Agreement, and its approval avoids a breach of contract that would materially adversely affect the business.

Negatives

• There is no assurance that a reverse stock split will result in a sustained increase in the stock price for any meaningful period or at all.
• A reverse stock split will reduce the total number of outstanding shares, which may lead to reduced trading volume and a smaller number of market makers, potentially decreasing liquidity.
• Some stockholders may end up owning 'odd lots' (less than 100 shares) after the split, which can incur incrementally higher transaction costs per share through certain brokers.
• The market may view a reverse stock split negatively, potentially leading to a decrease in the company's overall market capitalization if the per-share price does not increase proportionally.
• Stockholders will receive cash for fractional shares, which may be subject to brokerage fees and other expenses, and they will not have any further interest in the company with respect to those fractional shares.

Risks

• Failure to approve the Reverse Stock Split Amendment could prevent the company from complying with the Nasdaq Minimum Bid Price Requirement.
• Delisting from Nasdaq could lead to trading on an over-the-counter market, which typically has less liquidity, reduced investor interest, and fewer institutional participants, materially adversely affecting the common stock.
• Delisting could diminish the company's ability to maintain and obtain analyst coverage, attract investor interest, and access capital.
• There is no assurance that the reverse stock split, if completed, will result in a sustained increase in the price of the common stock or enhance the company's ability to engage in capital raising activities.
• The reverse stock split may decrease the liquidity of the common stock due as it reduces the total number of outstanding shares.
• The reverse stock split may result in some stockholders owning odd lots, which may be more difficult to sell or require greater transaction costs per share.
• The reverse stock split may lead to a decrease in the overall market capitalization of the company if the per share market price does not increase in proportion to the reverse split ratio.
• Breach of the terms of the Securities Purchase Agreement if stockholder approval for the Reverse Stock Split Amendment is not obtained, which would materially adversely affect the business and results of operations.

Future Outlook

The Board seeks authorization for a reverse stock split to maintain Nasdaq listing and enhance the company's ability to raise capital. The Board will determine the exact ratio and timing within one year of stockholder approval, considering factors such as the company's ability to maintain its Nasdaq listing, historical and prevailing trading price and volume of common stock, expected impact on the trading market, administrative costs, and general market and economic conditions. The company does not currently have plans to issue additional shares from the increased authorized but unissued pool, though some of these additional shares underlie warrants that could be exercised or converted after the reverse stock split is effected.

Management Comments

• "We are pleased to invite you to attend the special meeting of stockholders of Immunic, Inc."
• "Your vote is important. Regardless of whether you plan to attend the Special Meeting, it is important that your shares be represented and voted at the Special Meeting, and we hope you will vote as soon as possible."
• "Thank you for your ongoing support of, and continued interest in, Immunic, Inc."
• "The Board believes that the failure of stockholders to approve the Reverse Stock Split Amendment could prevent the Company from complying with the Minimum Bid Price Requirement and could, among other risks, inhibit our ability to conduct capital raising activities."
• "Management does not anticipate that the Company’s financial condition, the percentage ownership of Common Stock by management, the number of the Company’s stockholders or any aspect of the Company’s business will materially change as a result of the Reverse Stock Split Amendment."
• "The Board believes, however, that these potential effects are outweighed by the benefits of the Reverse Stock Split Amendment."

Industry Context

StockSavvy.ai notes that reverse stock splits are a common strategy for companies facing delisting from major exchanges like Nasdaq due to minimum bid price requirements. Maintaining a listing on a reputable exchange is crucial for institutional investor access, analyst coverage, and perceived corporate credibility, which are vital for biotechnology companies like Immunic that often rely on capital markets for funding research and development. The recent capital raise via warrants underscores the company's ongoing need for market access to support its operations and strategic initiatives.

Comparison to Industry Standards

• Many small-cap biotechnology companies, particularly those in clinical development stages, frequently encounter challenges in maintaining stock prices above exchange minimums. For example, companies like Sorrento Therapeutics and Cassava Sciences have also navigated Nasdaq compliance issues, sometimes resorting to reverse stock splits to avoid delisting.
• The proposed reverse split ratio range of 1-for-10 to 1-for-30 is consistent with typical industry practice for companies seeking to significantly boost their per-share price to meet listing requirements. Smaller peers often use similar mechanisms to maintain market appeal and compliance.
• The issuance of pre-funded warrants with a very low exercise price ($0.0001) combined with common warrants is a common financing structure for companies with low stock prices, allowing investors to participate while managing beneficial ownership limitations and providing immediate capital.

Corporate Governance

Stakeholder Impact

• Shareholders will see their number of shares reduced and per-share price increased proportionally. Those with fractional shares will receive cash payments. They may face higher transaction costs for odd lots. Their percentage ownership and proportionate voting power will not be affected.
• Institutional investors may gain access to the stock if the higher price meets their investment thresholds, potentially increasing trading volume and liquidity.
• Employees holding equity awards (options and warrants) will have the number of shares issuable upon exercise reduced proportionally, and their exercise prices will be adjusted.
• Creditors are not directly impacted, but maintaining Nasdaq listing could indirectly support the company's financial stability and access to capital, which benefits all stakeholders.

Next Steps

• Stockholders are to vote on the Reverse Stock Split Proposal at the Special Meeting on April 14, 2026.
• If approved, the Board of Directors will determine the final reverse stock split ratio (between 1-for-10 and 1-for-30, with an anticipated range of 1-for-10 to 1-for-20) and the timing of its implementation within one year of stockholder approval.
• The company will announce preliminary voting results at the Special Meeting and disclose final results in a Current Report on Form 8-K filed with the SEC within four business days after the meeting.
• The company must regain compliance with Nasdaq's $1.00 minimum bid price requirement by June 22, 2026.

Key Dates

Recommendation

Immunic is taking a necessary step to avoid delisting from Nasdaq, which is critical for its market access and ability to raise capital, especially given its recent warrant offering. While a reverse stock split itself does not change the company's fundamental value and carries risks like potential liquidity reduction and negative market perception, it is a crucial action to maintain exchange compliance. For existing investors, this move helps preserve the stock's tradability on a major exchange, justifying a 'hold' rather than a 'sell' due to the avoidance of a worse outcome (delisting). However, the underlying issues leading to the low stock price suggest caution, preventing a 'buy' recommendation.

Keywords

Immunic, IMUX, reverse stock split, Nasdaq compliance, delisting risk, proxy statement, special meeting, capital raise, stock liquidity, corporate governance, shareholder vote, pre-funded warrants, common warrants